Acute B Lymphoblastic Leukemia (B-ALL), Acute T Lymphoblastic Leukemia (T-ALL)
Conditions
Brief summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Interventions
DRUGinjection of BEP 800
injection of BEP 800
OTHERControl
no injection of BEP 800
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
Exclusion criteria
* Patient over 80 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Viability on primary ALL samples | 2 years | The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect on SRC phosphorylation | 2 years | The effect of BEP-800 on T-ALL and B-ALL will be evaluated by flow cytometry by measuring HSP90 and SRC (phosphorylated), by intracellular labeling after permeabilization of the cells, 18 hours after treatment with BEP-800. |
Countries
France
Contacts
Primary ContactFrançois GIRODON
Outcome results
None listed